Treatment sequences with bevacizumab at first-line and targeted biologics at third-line may not be cost-effective at the commonly used threshold of $100,000/QALY gained but a marginal decrease in the cost of bevacizumab may make treatment sequences with first-line bevacizumab cost-effective. Future economic evaluations should validate the study results using parameters from ongoing clinical trials.
Article